Digital banking software provider Backbase has appointed Chris Vanden Berghe as Regional Vice President of Technology for Asia Pacific. The new role is based in Singapore and will drive the

The post Backbase Appoints Chris Vanden Berghe as Regional VP of Technology for APAC appeared first on Fintech Singapore.

The funding is made up of $35m in equity and $115m in debt to fund further expansion.

Company increased customers, expanded protected mailboxes and earned numerous award recognitions in 2021

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/ironscales_adds_more_than_3_000_customers_remediates_27_million_emails/prweb18477166.htm

Noted IT and cybersecurity industry executives Raj Badhwar, former SVP and Global CISO at Voya Financial, and Kurt John, Chief Cybersecurity Officer at Siemens USA will join the current advisory board...

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/2022/02/prweb18481289.htm

Successful execution of data center network automation strategies will be essential to ongoing digital operations. New research from EMA has found that only 23% of enterprises and service providers...

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/ema_will_share_insights_from_new_the_future_of_data_center_network_automation_research_report_during_webinar/prweb18480667.htm

HONG KONG, Feb 7, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, an Investigational New Drug application ("IND", for multiple sclerosis) for SN1011 has been filed with and accepted, on 28 January 2022, by the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration of China (the "NMPA"). The Company plans to initiate the Phase II clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of multiple sclerosis.

SN1011 is the Company's third generation, covalent reversible BTK inhibitor designed for higher selectivity, superior efficacy and improved safety for the long-term treatment of systemic lupus erythematous, pemphigus vulgaris, multiple sclerosis, rheumatoid arthritis, and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "after the Company announced earlier the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03, an IND application (for multiple sclerosis) for SN1011 has been filed with and accepted by the Center for the CDE of the NMPA, which will accelerate the progression of the Phase II clinical study and clinical development program related to indication for treatment of multiple sclerosis, fully reflecting the Company's efficient implementation of new drug R&D programs. We are absolutely confident in the enormous prospects of SN1011's clinical development. In the future, the Company will accelerate the program to further expand its product pipeline and strive to bring benefits to patients."

About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022,

Ethereum’s market cap sits at $360.37 billion which is larger than the valuation of top brands in the world. Since launch, the asset has played second fiddle to Bitcoin and has had to grapple with some of the sternest challenges that threatened its existence. The community is confident that the dark days are over and […]

Lithuania-based fintech startup iDenfy partners with European Merchant Bank, a dynamic digital bank licensed by the European Central Bank. The opportunities today are vastly different than just decades ago. The technological development we have achieved has paved the way for various industries to grow at a pace never seen before. Additionally, the transition to cyberspace […]

The post iDenfy establishes a partnership with European Merchant Bank to help the company attain its goals appeared first on Fintech News.

Attack Wagon blockchain provides users an immersive gaming experience. $ATK is a Polygon chain-based ERC-20 token. ATK token fuels the ...

Read More...

Robinhood CEO has hinted at a potential listing of Shiba Inu and other Cryptos on the platform. He stated that he has heard the voices of users but they have to adopt a cautious approach to avoid trouble with regulators. The Shiba Inu community has been vocal in getting the asset listed on popular cryptocurrency […]

Oil Crude prices seem to have a one-way ticket to $100 oil.  This week’s rally in crude was supported by the OPEC+ decision to stick to their gradual increase strategy and as US production fell again.  An artic blast is also disrupting some production in Texas and that is driving this latest price surge. Initially […]

Digital monetisation platform Gather has relaunched Gather Online, a product that allows publishers to earn revenue without ads. The venture, which has been four years in the making, leverages Gather’s hybrid proof of work/proof of stake blockchain to establish what the startup calls a “creators’ network” that disrupts the traditional advertising model. Go-Time for Gather [...]

The post Gather Relaunches Online Product to Disrupt Digital Advertising Model appeared first on Blockonomi.